Trial reportCancer science2021
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- The Efficacy of Polatuzumab Vedotin Targeting CD79B in the Treatment of Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.Cancer research and treatment · 2023Pooled it
- Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma.Journal of comparative effectiveness research · 2023Pooled it
- Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.International journal of clinical oncology · 2025Trial
- Trial
- A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.Cancer science · 2021Trial
- Comprehensive assessment of DeVIC therapy for relapsed or refractory diffuse large B-cell lymphoma.International journal of hematology · 2026Article
- Article
- Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma.International journal of hematology · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Long-term complete remission following treatment with polatuzumab vedotin, rituximab, and bendamustine in a patient with mantle cell lymphoma relapsing after CAR-T cell therapy: a case report.Therapeutic advances in medical oncology · 2026Article
- Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma.World journal of gastroenterology · 2025Article
- Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China.Scientific reports · 2025Article
- Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.Blood advances · 2025Article
- Predictive levels of vascular endothelial growth factor (VEGF), thymidine kinase 1 (TK1) with interleukin-6 (IL-6), plasma T cells, NK cells as well as B cells in treating diffuse large B-cell lymphoma receiving rituximab.Journal of medical biochemistry · 2025Article
- Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma.Annals of hematology · 2025Article
- Eliminating VEGFA+ tumor-associated neutrophils by antibody-drug conjugates boosts antitumor immunity and potentiates PD-1 immunotherapy in preclinical models of cervical cancer.Cell death & disease · 2025Article
- Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study.Therapeutic advances in hematology · 2025Article
- Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives.Frontiers in pharmacology · 2025Review
- Poor outcome of older patients with diffuse large B-cell lymphoma after progression.Journal of clinical and experimental hematopathology : JCEH · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 18 institutions in 1 country.
Yasuhito TeruiDepartment of Hematology and Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Shinya RaiDepartment of Hematology and Rheumatology, Kindai University Hospital, Osaka, Japan.ORCID https://orcid.org/0000-0003-3929-9751
Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9129-8057
Motoko YamaguchiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan.
Jun TakizawaDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Junya KurodaDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Koji KatoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-5815-4585
Youko SuehiroDepartment of Hematology, Kyushu Cancer Center, Fukuoka, Japan.
Noriko FukuharaDepartment of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan.
Ken OhmineDepartment of Hematology, Jichi Medical University Hospital, Tochigi, Japan.
Hideki GotoDepartment of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Kazuhito YamamotoDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Aichi, Japan.
Nobuhiro KanemuraFirst Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.
Yasunori UedaDepartment of Hematology, Kurashiki Central Hospital, Okayama, Japan.
Kenichi IshizawaDepartment of Third Internal Medicine, Yamagata University Hospital, Yamagata, Japan.
Kyoya KumagaiDepartment of Hematology and Medical Oncology, Chiba Cancer Center, Chiba, Japan.
Atsuko KawasakiChugai Pharmaceutical Co, Ltd, Tokyo, Japan.
Tomohisa SaitoChugai Pharmaceutical Co, Ltd, Tokyo, Japan.
Misato HashizumeChugai Pharmaceutical Co, Ltd, Tokyo, Japan.
Hirohiko ShibayamaDepartment of Hematology and Oncology, Osaka University Hospital, Osaka, Japan.
Aichi Cancer Center · JPChiba Cancer Center · JPGifu University Hospital · JPHokkaido University · JPJichi Medical University · JPKindai University Hospital · JPKobe City Medical Center General Hospital · JPKurashiki Central Hospital · JPKyoto Prefectural University of Medicine · JPKyushu University · JPMie University · JPNational Hospital Organization Kyushu Cancer Center · JPNiigata University · JPOsaka University Hospital · JPThe Cancer Institute Hospital · JPTohoku University Hospital · JPTokyo National Hospital · JPYamagata University Hospital · JP
Funding
Chugai Pharmaceutical Co., Ltd
Abstract
Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine 90 mg/m
Indexed as
AgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideDrug Administration ScheduleDrug Resistance, NeoplasmGranulocyte Colony-Stimulating FactorHumansImmunoconjugatesJapanLymphoma, Large B-Cell, DiffuseMiddle AgedPositron Emission Tomography Computed TomographyProgression-Free SurvivalRituximabAntibodies, MonoclonalBendamustine HydrochlorideGranulocyte Colony-Stimulating FactorImmunoconjugatespolatuzumab vedotinRituximabbendamustinediffuse large B-cell lymphomapolatuzumab vedotinrelapsed/refractory (R/R)rituximab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.